# EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

> **NCT03266653** · PHASE2 · RECRUITING · sponsor: **New York Medical College** · enrollment: 20 (estimated)

## Conditions studied

- Epstein-Barr Virus Infections
- Primary Immune Deficiency Disorder

## Interventions

- **DRUG:** cytotoxic t-lymphocytes

## Key facts

- **NCT ID:** NCT03266653
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03266653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03266653, "EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03266653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*